News › Markets  ·  28 Aug 2026, 1:32 PM IST  ·  4 days ago

JM Financial calls Metropolis Healthcare ‘best-value diagnostic stock’, sees up to 27% upside

Bias: Neutral 0

In one line — JM Financial has retained its Buy rating on Metropolis Healthcare with a target price of Rs 734, implying 27.2% upside. The brokerage calls it the cheapest among India’s leading listed diagnostic players, citing attracti

Bearish
Bullish
−10000+100

Source: Economic Times · AI-summarised by Anadi · Updated 28 Aug 2026, 1:47 PM IST

What Happened

JM Financial has retained its Buy rating on Metropolis Healthcare with a target price of Rs 734, implying 27.2% upside. The brokerage calls it the cheapest among India’s leading listed diagnostic players, citing attractive valuations, network expansion, stronger B2C growth and improving margins as key drivers.